Related references
Note: Only part of the references are listed.5,10-Methenyltetrahydrofolate synthetase activity is increased in tumors and modifies the efficacy of antipurine LY309887
Martha S. Field et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2009)
Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: The Children's Oncology Group
Suman Malempati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours
K. Nakagawa et al.
BRITISH JOURNAL OF CANCER (2006)
Regulation of de novo purine biosynthesis by methenyltetrahydrofolate synthetase in neuroblastoma
MS Field et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer
CM Ulrich et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent
AA Adjei
CLINICAL CANCER RESEARCH (2004)
Folic acid food fortification is associated with a decline in neuroblastoma
AE French et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma
GV Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Review of a promising new agent - Pemetrexed disodium
L Paz-Ares et al.
CANCER (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)